Newsmaker: Dr. Anette Duensing
Dr. Anette Duensing
Noteworthy: Duensing received funding from the GIST Cancer Research Fund — a patient-driven organization that funds research on gastrointestinal stromal tumors, or GISTs. This is the seventh consecutive year that the fund has supported research in Duensing's laboratory.
Family: Husband, Stefan
Occupation: Assistant professor of pathology, University of Pittsburgh School of Medicine
Background: In 2000, during her postdoctoral fellowship at Brigham and Women's Hospital in Boston, Duensing experienced firsthand the tumor remission of the first GIST patient treated with the therapy drug Gleevec. Since then, her research has focused on a better molecular understanding of the biology of GISTs and the mode of action of Gleevec. Duensing joined the University of Pittsburgh Cancer Institute in 2003.
Education: Medical degree from the University of Hannover Medical School, Hannover, Germany, in 1997
Quote: “This generous funding has allowed us to significantly expand our efforts identifying novel treatment options for GIST patients — in particular for patients whose tumors have become resistant to Gleevec over time.”
— Chris Togneri
Show commenting policy
TribLive commenting policy
You are solely responsible for your comments and by using TribLive.com you agree to our Terms of Service.
We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.
While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.
We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers.
We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.
We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.
We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.
We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.
- PennDOT team decides what spells trouble on vehicle license plates
- Newsmaker: Lauren Bailey
- Film shares tale of Pittsburgh man who turned disability into career
- Bookings for August Wilson Center climb, but permanent board yet to be set
- La Scuola d’Italia Galileo Galilei stokes interest in Pittsburgh’s Italian heritage
- Allegheny County Council aims to dig out of hole
- Count of Three Rivers Regatta visitors could top 500K despite race ban
- Carnegie man sought after hammer attack, police say
- Fatal crash under investigation in Baden
- Court attire can have impact, public defenders say
- Man, child hit by car late Saturday in South Side